摘要
目的比较阿立哌唑（商品名博思清）和齐拉西酮（商品名力复君安）治疗精神分裂症的疗效和安全性。方法将84例符合CCMD-3的精神分裂症患者随机分为两组,分别给予阿立哌唑和齐拉西酮治疗8周。采用阳性症状与阴性症状量表（PANSS）评定临床疗效,不良反应症状量表（TESS）评定不良反应。结果阿立哌唑组和齐拉西酮组治疗8周后的有效率分别为90.5%和92.9%,两药疗效无显著性差异（P〉0.05）。阿立哌唑组的副反应发生率（35.7%）低于齐拉西酮组（38.0%）,但无显著性差异（P〉0.05）。齐拉西酮组锥体外系副反应发生率均明显高于阿立哌唑组（40.4%vs4.8%,P〈0.05）,阿立哌唑组出现恶心呕吐,头痛,头昏和晕厥及嗜睡的比例明显高于齐拉西酮组（64.3%vs7.1%,P〈0.05）。但两药引起的副反应一般为轻度或中度,患者耐受性较好。结论阿立哌唑和齐拉西酮对精神分裂症的疗效相当,但副作用有所不同。
Objective To compare efficacy and safety of Aripiprazole and Ziprasidone in the treatment of schizophrenia. Methods 84 patients with schizophrenia by CCMD-3 were randomly allocated to two groups treated with Aripiprazole or Ziprasidone for 8 weeks, the Positive and Negative Syndrom Scale （PANSS） and Treatment Emergent Symptoms Scale （TESS） were used to evaluate efficacy and adverse effects respectively before and at the ends of 2,4,8 weeks of treatment, Results The total effective rates for the Aripiprazole and Ziprasidone groups were 90.5% and 92.5% respectively after 8 weeks. There was no significant difference between the two groups（P〉 0.05）. Incidence of adverse effects in the Aripiprazole group was lower than that in the Ziprasidone group, but the difference was not significant（P〉 0.05）. The rates of extrapyramidal symptoms were significantly higher in the Ziprasidone group than those in the Aripiprazole group（40.4%vs4.8% ,P〈 0.05）. The rates of nausea, vomit, headache, dizzy, drowsy were significantly higher in the Ziprasidone group than those in the Aripiprazole group（64.3% vs7.1%,P〈 0. 05）.But these side effects were not serious, and patients often had good torlerability for them. Conclusions The results suggest that Aripiprazole is as effective as Ziprasidone for the treatment of schizophrenia, but two agents have different side effects profile.
出处
《国际医药卫生导报》
2007年第11期77-79,共3页
International Medicine and Health Guidance News
